wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q28083386-27EF8A6F-EBD1-4552-AF9D-721F1688EA81
Q28083386-27EF8A6F-EBD1-4552-AF9D-721F1688EA81
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28083386-27EF8A6F-EBD1-4552-AF9D-721F1688EA81
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it
P2860
Q28083386-27EF8A6F-EBD1-4552-AF9D-721F1688EA81
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28083386-27EF8A6F-EBD1-4552-AF9D-721F1688EA81
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
09eb958db3e64651c3d8fd29777cb9f79cc99ea9
P2860
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.